--- title: "Amylyx's Big Trial Win, Intapp's AI Push, and HWH's Nasdaq Struggle" type: "News" locale: "en" url: "https://longbridge.com/en/news/296894464.md" description: "This roundup covers major corporate moves across sectors, from Amylyx's Phase 3 trial success and massive financing to Intapp's launch of its new AI colleague. We also track O'Reilly's multi-million dollar spam settlement alongside its record earnings." datetime: "2026-08-25T10:12:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296894464.md) - [en](https://longbridge.com/en/news/296894464.md) - [zh-HK](https://longbridge.com/zh-HK/news/296894464.md) generator: "portal-rs" --- # Amylyx's Big Trial Win, Intapp's AI Push, and HWH's Nasdaq Struggle Here is what is going on this week. We are seeing major swings in the biotech space and fresh AI software deployments, while some legacy retailers and manufacturers deal with legal and operational headaches. **The big biotech moves.** Amylyx Pharmaceuticals (AMLX.US) is riding high after its Phase 3 LUCIDITY trial showed a 55% drop in severe hypoglycemic events. With an NDA submission planned by late 2026, the company capitalized on the news with a massive $500 million stock offering. Meanwhile, Protagonist Therapeutics (PTIX.US) remains resilient near recent highs following a strong second quarter, driven by royalty revenues that prompted Wall Street analysts to bump their price targets significantly. **Software and automation.** Intapp (INTS.US) is leaning hard into artificial intelligence, rolling out "Celeste," an expert-level AI colleague designed for professional services. The launch has already attracted major clients looking to boost their international expansion. On the operational front, HWH International (HWH.US) secured a $10 million PIPE financing deal as it plots an expansion of its robotics division into the US. However, HWH continues to grapple with Nasdaq equity compliance issues. **Retail and industrial headaches.** Despite posting record Q2 earnings, O'Reilly Automotive (ORLY.US) has agreed to an $18.8 million settlement to resolve a class-action lawsuit over unsolicited text messages. Over in the manufacturing sector, Toyo Tire (TYOYY.US) slashed its full-year profit guidance after Q2 missed expectations due to production snags, even as its Georgia plant celebrated producing its 100 millionth tire. Delek US Holdings (DKI.US) and Kosmos Energy (KOS.US) both reported solid second-quarter results, with Kosmos posting a robust $185 million in net income. **Also this week:** - PIMCO Active Bond ETF (BOND.US) maintains a massive footprint with around $8.56 billion in assets under management, reflecting steady investor interest in high-quality, actively managed bond portfolios. - RSSX (RSSX.US) continues to navigate the broader market environment as investors monitor the latest sector shifts and strategic updates. ### Related Stocks - [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md) - [ORLY.US](https://longbridge.com/en/quote/ORLY.US.md) - [HWH.US](https://longbridge.com/en/quote/HWH.US.md) - [INTS.US](https://longbridge.com/en/quote/INTS.US.md) - [PTIX.US](https://longbridge.com/en/quote/PTIX.US.md) - [DKI.US](https://longbridge.com/en/quote/DKI.US.md) - [KOS.US](https://longbridge.com/en/quote/KOS.US.md) - [TYOYY.US](https://longbridge.com/en/quote/TYOYY.US.md) ## Related News & Research - [Amundi Cuts Stock Position in O'Reilly Automotive, Inc. $ORLY](https://longbridge.com/en/news/298178913.md) - [O'Reilly Automotive, Inc. $ORLY Shares Bought by Ironvine Capital Partners LLC](https://longbridge.com/en/news/297752336.md) - [Amylyx signs Bachem manufacturing deal for avexitide supply starting 2028](https://longbridge.com/en/news/298364899.md) - [Kosmos Energy to partially redeem $25M of 7.750% notes due 2027, redemption set for Sept. 18](https://longbridge.com/en/news/298302105.md) - [O'Reilly Automotive director Thomas Hendrickson sells 1,000 common shares for $87,831.1](https://longbridge.com/en/news/297695708.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**